LEADER 03692nam  22006735  450 
001 9910438020403321
005 20200630072634.0
010   $a1-907673-58-X
024 7 $a10.1007/978-1-907673-58-0
035   $a(CKB)3710000000031202
035   $a(EBL)1592996
035   $a(OCoLC)868915416
035   $a(SSID)ssj0001067844
035   $a(PQKBManifestationID)11696861
035   $a(PQKBTitleCode)TC0001067844
035   $a(PQKBWorkID)11093045
035   $a(PQKB)10822021
035   $a(DE-He213)978-1-907673-58-0
035   $a(MiAaPQ)EBC1592996
035   $a(PPN)176102604
035   $a(EXLCZ)993710000000031202
100   $a20131112d2013      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aPrevention of Nausea and Vomiting in Cancer Patients /$fby Matti Aapro, Karin Jordan, Petra Feyer
205   $a1st ed. 2013.
210  1$aTarporley :$cSpringer Healthcare Ltd. :$cImprint: Springer Healthcare,$d2013.
215   $a1 online resource (63 p.)
300   $aDescription based upon print version of record.
311   $a1-908517-87-5 
320   $aIncludes bibliographical references.
327   $aIntroduction -- Pathophysiology and classification of chemotherapy-induced nausea and vomiting -- Risk factors associated with nausea and vomiting after chemotherapy -- Risk factors associated with nausea and vomiting after radiotherapy -- Antiemetic drugs -- Antiemetic prophylaxis of chemotherapy-induced nausea and vomiting -- Antiemetic prophylaxis of radiotherapy-induced nausea and vomiting -- Summary of the approach to treatment of chemotherapy-induced nausea and vomiting -- Conclusions and future directions.
330   $aTreatment tolerance is a challenge for most cancer patients, and it is therefore essential that healthcare professionals (HCPs) are quick to recognize adverse events and implement management strategies to address them. Prevention of Nausea and Vomiting in Cancer Patients provides comprehensive guidance on managing nausea and vomiting, which are common and often severe adverse events experienced by patients receiving chemotherapy and radiotherapy. The book refers to the latest American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), and Multinational Association for Supportive Care in Cancer (MASCC) guidelines and will be a useful resource for oncologists, oncology fellows, general physicians, and other HCPs wishing to learn more about the effective management of chemotherapy-and radiotherapy-induced nausea and vomiting in cancer patients.
606   $aOncology  
606   $aRadiotherapy
606   $aPharmacotherapy
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aRadiotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H29056
606   $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000
615  0$aOncology  .
615  0$aRadiotherapy.
615  0$aPharmacotherapy.
615 14$aOncology.
615 24$aRadiotherapy.
615 24$aPharmacotherapy.
676   $a610
676   $a615.1
676   $a615.58
676   $a615842
700   $aAapro$b Matti$4aut$4http://id.loc.gov/vocabulary/relators/aut$0922665
702   $aJordan$b Karin$4aut$4http://id.loc.gov/vocabulary/relators/aut
702   $aFeyer$b Petra$4aut$4http://id.loc.gov/vocabulary/relators/aut
906   $aBOOK
912   $a9910438020403321
996   $aPrevention of Nausea and Vomiting in Cancer Patients$92070446
997   $aUNINA